A 2023 study out of the University of British Columbia linked GLP-1 agonists to a heightened risk of severe gastrointestinal problems. These problems include gastroparesis, pancreatitis, and bowel obstruction
After 9 months on Retatrutide, he achieved a 20% weight loss, dramatically improved lipid levels, normalized blood pressure, and decreased CRP by over 50%, profoundly reducing his cardiovascular risk
Normally, patients fast before surgery to reduce this risk, but GLP-1 medications can cause food to remain in the stomach longer than expected, increasing the chance of aspiration even after fasting
Impact of early SGLT2 inhibitors prescription on acute decompensated heart failure outcomes: insights from a real-world setting
Wong, M
2021 Mar 9;12:2042018821997320